BBLG Bone Biologics Corp
Research report · from SEC EDGAR · close 2026-07-31
executive summary
Bone Biologics Corp (BBLG) is a $1.5M company. Revenue is $1.07B (+0.0% y/y) at a -0% net margin. It is not yet profitable. Our health score is F (33/100). 2 red flags on file. It may need to raise cash (dilution risk).
Revenue (FY)
$1.07B
+0.0% y/y
⛔Going-concern warning
Auditor flagged substantial doubt about the company continuing for the next 12 months — a raise is usually required.
⚠Active dilution shelf
An effective S-3 shelf with 2 prospectus filing(s) in 12 months — shares may be getting sold into the market.
who's buying
Insider buys / sells
0 / 0
Cash & ST investments
$6.2M
Operating cash flow
-$2.7M
Dilution shelf
active shelf
Assembled from SEC EDGAR (XBRL, Form 4, 13F, filings), STOCK Act disclosures, and end-of-day prices — every figure is real and sourced; nothing is fabricated or predicted. Filings lag 40–90 days. Educational, not investment advice. Generated 2026-07-31 by stocktools.ai.